Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655840 | 0.92 | BLM (0.42) | BLMKMT2APKMALDH1A1MEN1 | |
| SCHEMBL7435719 | 0.83 | L3MBTL1 (0.47) | KMT2APKMALDH1A1MEN1CHRNB2 | |
| SCHEMBL25630712 | 0.80 | BLM (0.46) | BLMKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL2739418 | 0.80 | BLM (0.57) | BLMKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL20756575 | 0.80 | BLM (0.57) | BLMKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL180620 | 0.80 | — | — | |
| SCHEMBL7431273 | 0.79 | L3MBTL1 (0.58) | KMT2AMEN1NPC1 | |
| Ethylene SCHEMBL8379639 | 0.79 | L3MBTL1 (0.44) | KMT2APKMALDH1A1MEN1CHRNB2 | |
| SCHEMBL9139551 | 0.78 | L3MBTL1 (0.67) | KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL4967184 | 0.77 | KMT2A (0.42) | KMT2APKMALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206884-A1 | ULTRAVIOLET RADIATION-CURABLE POLYSILOXANE COMPOSITION, AND DAMPING MATERIAL | TAICA CORPORATION (JP) | 2025-06-26 | — | — | US | disclosed |
| CN-118974144-A | Ultraviolet-curable polysiloxane composition and damping material | 株式会社泰已科 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023189433-A1 | ULTRAVIOLET RADIATION-CURABLE POLYSILOXANE COMPOSITION, AND DAMPING MATERIAL | 株式会社タイカ | 2023-10-05 | — | — | WO | disclosed |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-10259796-B2 | Oxaspiro[2.5]octane derivatives and analogs | ZAFGEN, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| EP-2683706-B1 | OXASPIRO [2.5]OCTANE DERIVATIVES AND ANALOGS | ZAFGEN INC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-5755993-A | Peroxygen bleach composition activated by piperidone derivatives | COLGATE-PALMOLIVE CO. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997024429-A9 | PEROXYGEN BLEACH COMPOSITION ACTIVATED BY PIPERIDONE DERIVATIVES | — | 1997-09-04 | — | — | WO | disclosed |
| WO-1997024429-A1 | PEROXYGEN BLEACH COMPOSITION ACTIVATED BY PIPERIDONE DERIVATIVES | COLGATE-PALMOLIVE COMPANY (US) | 1997-07-10 | — | — | WO | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | BLM 3468/4885KMT2A 4160/4885PKM 4415/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | BLM 3656/4885KMT2A 4093/4885PKM 4331/4885 |
| US-10259796-B2 | Oxaspiro[2.5]octane derivatives and analogs | OXER1, ACOX3, OXGR1 | BLM 3094/4885KMT2A 3590/4885PKM 1221/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | BLM 1443/4885KMT2A 1218/4885PKM 1135/4885 |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | BLM 1344/4885KMT2A 1425/4885PKM 3639/4885 |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | HRH2, PTGDR2, HRH1 | BLM 4073/4885KMT2A 3790/4885PKM 3146/4885 |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BLM 1437/4885KMT2A 1501/4885PKM 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.